U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511127) titled 'Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT' on March 13.
Brief Summary: To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Study Start Date: Feb. 28
Study Type: INTERVENTIONAL
Condition:
Hematologic Malignancy
Intervention:
DRUG: Maribavir
During the treatment period, maribavir is administered orally at a dosage of 400 mg twice daily. Participants will be stratified by clinical trial and received oral medication for varying durations.
Recruitment Status: RECRUITING
Sponsor: Ruiji...